drug
midostaurin
Marketedupdated 3mo agoby Lupin Ltd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying midostaurin
- phase2A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- phase3Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
- phase1Revumenib in Combination With 7+3 + Midostaurin in AML
- phase2Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
- phase2Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
- phase2A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
- phase3A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
- phase2Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 9, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 2, 2030method-of-use (U-2008)US 85751464.3y
- Oct 9, 2028method-of-use (U-2007)US 79730312.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that